Anavex Life Sciences Corporation

NASDAQ:AVXL   3:59:51 PM EDT
20.73
-0.31 (-1.47%)
Products, Regulatory

Anavex Life Sciences Announces Anavex®2-73 (Blarcamesine) Improved Both Primary Cognitive And Secondary Mds-Updrs Efficacy Endpoints With Significant Biomarker Correlation In Placebo-Controlled

Published: 06/28/2021 12:47 GMT
Anavex Life Sciences Corporation (AVXL) - Anavex Life Sciences Announces Anavex®2-73 (blarcamesine) Improved Both Primary Cognitive and Secondary Mds-updrs Efficacy Endpoints With Significant Biomarker Correlation in Placebo-controlled Phase 2 Clinical Trial for the Treatment of Patients With Par.
Anavex Life Sciences Corp - Anavex 2-73 Treatment Resulted in Significant (p = 0.035) Mrna Expression Increase of Sigmar1.
Anavex Life Sciences - Anavex 2-73 High Dose Showed Statistically Significant Improvement Compared to Placebo for Mds-updrs Total Score (p = 0.034).
Anavex Life Sciences Corp - From Baseline to End of Trial at 14 Weeks, Mds-updrs Total Score Improved by -10.98 Points in Anavex 2-73 High Dose Group.